AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11668230 — intervention group
Group type: COMPARATOR
Intervention: TEP without dissection balloon
Number of subjects: 44
Study 9832000 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine (group 1, n = 69)
Number of subjects: 211
Study 9832000 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal polysaccharide vaccine (group 2, n = 72)
Number of subjects: 211
Study 9832000 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B virus vaccine (group 3, n = 70)
Number of subjects: 211
Study 8130046 — intervention group
Group type: COMPARATOR
Intervention: morphine 0.15 mg kg‐1 and metoclopramide 10 mg
Number of subjects: 225
Study 8130046 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.15 mg kg‐1 and glycopyrronium 5 micrograms kg‐1
Number of subjects: 225
Study 8130046 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.15 mg kg‐1 and hyoscine 5 micrograms kg‐1
Number of subjects: 225
Study 2604925 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 22
Study 2604925 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 22
Study 2604925 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 2604925 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with visible physical disability
Number of subjects: 22
Study 29431140 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel task-specific centre-based group programme
Number of subjects: 60
Study 29431140 — intervention group
Group type: COMPARATOR
Intervention: Parent-led home-based programme
Number of subjects: 60
Study 26733277 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (initial dose 5-10 mg per day followed by flexible doses 5-15 mg per day)
Number of subjects: 42
Study 26733277 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (initial dose 2-4 mg per day followed by flexible doses 4-6 mg per day)
Number of subjects: 42
Study 25184356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin 200 to 400 mg BID
Number of subjects: 61
Study 25184356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 25184356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapropterin
Number of subjects: 61
Study 20634016 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-only CPR (HO-CPR)
Number of subjects: 17
Study 20634016 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR (STD-CPR)
Number of subjects: 17
Study 20005545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia at rest
Number of subjects: 0
Study 20005545 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia after handgrip
Number of subjects: 0
Study 20005545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hyperoxia and handgrip
Number of subjects: 0
Study 20005545 — intervention group
Group type: COMPARATOR
Intervention: Normoxic condition handgrip
Number of subjects: 0
Study 17574795 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified therapeutic community (TC) track with psychoeducational seminar, trauma-informed addictions treatment, and case management
Number of subjects: 34
Study 17574795 — intervention group
Group type: COMPARATOR
Intervention: Basic program services (Control group)
Number of subjects: 34
Study 15748090 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/day
Number of subjects: 251
Study 15748090 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine 75-150 mg/day
Number of subjects: 251
Study 15748090 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 251
Study 15748090 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 251
Study 11262776 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructive procedures in surgical treatment of tumors
Number of subjects: 56
Study 9715201 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX) 80 mg/400 mg orally three times daily for 10 days
Number of subjects: 40
Study 9715201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7978398 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ondansetron
Number of subjects: 589
Study 7978398 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 589
Study 7978398 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 589
Study 7978398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study 2648609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear solution with polyvinyl alcohol 1.4% m/v preserved with 0.5% m/v chlorobutanol
Number of subjects: 16
Study 2648609 — intervention group
Group type: COMPARATOR
Intervention: Tear solutions without chlorobutanol
Number of subjects: 16
Study 31955998 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional fluoroscopy
Number of subjects: 206
Study 31955998 — intervention group
Group type: COMPARATOR
Intervention: 2-dimensional fluoroscopy
Number of subjects: 206
Study 27862715 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT=ON
Number of subjects: 328
Study 27862715 — intervention group
Group type: COMPARATOR
Intervention: CRT=OFF
Number of subjects: 328
Study 25955086 — intervention group
Group type: EXPERIMENTAL
Intervention: PCM Cervical Disc
Number of subjects: 293
Study 25955086 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 293
Study 23952854 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 662
Study 21849377 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually adjusted, progressive and specific balance group training, three times a week for three months
Number of subjects: 59
Study 19935020 — intervention group
Group type: EXPERIMENTAL
Intervention: 21/7-day norgestimate/ethinyl E2 25-microgram OCP
Number of subjects: 332
Study 19935020 — intervention group
Group type: COMPARATOR
Intervention: 24/4-day drospirenone/ethinyl E2 20-microgram OCP
Number of subjects: 332
Study 17241751 — intervention group
Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 549
Study 17241751 — intervention group
Group type: EXPERIMENTAL
Intervention: 68-78 Gy to the SVs
Number of subjects: 549
Study 15542065 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets from NIDDM patients in a medium containing 180 mg/dL glucose
Number of subjects: 0
Study 15542065 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets from NIDDM patients in a medium containing 90 mg/dL glucose
Number of subjects: 0
Study 15542065 — intervention group
Group type: COMPARATOR
Intervention: Control platelets
Number of subjects: 0
Study 11359198 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinesterasic pesticides exposure (measured by AChE and BChE levels)
Number of subjects: 55
Study 11359198 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-economic factors (educational level)
Number of subjects: 55
Study 9573749 — intervention group
Group type: COMPARATOR
Intervention: Standard-size cuff (RCS)
Number of subjects: 1791
Study 9573749 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-size cuff (LCS)
Number of subjects: 1791
Study 9573749 — intervention group
Group type: EXPERIMENTAL
Intervention: Android obesity (LCS subgroup)
Number of subjects: 1791
Study 9573749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynoid obesity (LCS subgroup)
Number of subjects: 1791
Study 8158885 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 121
Study 8158885 — intervention group
Group type: COMPARATOR
Intervention: Control (other antihypertensive treatments excluding ACE inhibitors)
Number of subjects: 121
Study 30232856 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (puncturing specific acupoints with filiform needles, once every other day for 8 weeks)
Number of subjects: 58
Study 30232856 — intervention group
Group type: COMPARATOR
Intervention: Medication treatment (Omeprazole capsules, 20 mg twice a day for 8 weeks)
Number of subjects: 58
Study 27632953 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach (AA) for hepatectomy
Number of subjects: 0
Study 27632953 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (CA) for hepatectomy
Number of subjects: 0
Study 27632953 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach (AA) for hepatectomy in patients with large-size tumor (>5 cm)
Number of subjects: 0
Study 27632953 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (CA) for hepatectomy in patients with large-size tumor (>5 cm)
Number of subjects: 0
Study 27632953 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach (AA) for hepatectomy in patients with small-size tumor (≤5 cm)
Number of subjects: 0
Study 27632953 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (CA) for hepatectomy in patients with small-size tumor (≤5 cm)
Number of subjects: 0
Study 25321941 — intervention group
Group type: EXPERIMENTAL
Intervention: LipiFlow (automated thermodynamic treatment)
Number of subjects: 26
Study 22386977 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training program (8 weeks, 3 times a week on a vibration platform)
Number of subjects: 31
Study 22386977 — intervention group
Group type: COMPARATOR
Intervention: Control group (home-based physical therapy program without vibration training)
Number of subjects: 31
Study 20143872 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg of folic acid daily for 12 weeks
Number of subjects: 0
Study 18317323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-fidelity simulation
Number of subjects: 0
Study 16573801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 90 mg, 6 mg/h
Number of subjects: 36
Study 16573801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole orally disintegrating tablet 60 mg every 6 h
Number of subjects: 36
Study 16573801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 120 mg, 9 mg/h
Number of subjects: 36
Study 16573801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 120 mg, 6 mg/h
Number of subjects: 36
Study 14523765 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 100
Study 14523765 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 100
Study 10808678 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary amenorrhea patients
Number of subjects: 36
Study 10808678 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary amenorrhea patients
Number of subjects: 36
Study 10808678 — intervention group
Group type: COMPARATOR
Intervention: Control group (regularly menstruating women)
Number of subjects: 36
Study 8765377 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 426
Study 8765377 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide
Number of subjects: 426
Study 8765377 — intervention group
Group type: EXPERIMENTAL
Intervention: cisapride
Number of subjects: 426
Study 8765377 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 426
Study 1558237 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active motion
Number of subjects: 75
Study 1558237 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion
Number of subjects: 75
Study 1558237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both early active motion and continuous passive motion
Number of subjects: 75
Study 2868941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 41
Study 2868941 — intervention group
Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 41
Study 30621692 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants of ISRT (cases)
Number of subjects: 1208
Study 30621692 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (controls)
Number of subjects: 1208
Study 30105459 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 0
Study 30105459 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 30105459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27286745 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (2.9% delta 9-THC)
Number of subjects: 42
Study 27286745 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (6.7% delta 9-THC)
Number of subjects: 42
Study 27286745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24361229 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with assessment of response at week 12 using anatomic imaging (CT/MRI)
Number of subjects: 338
Study 24361229 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with assessment of response at week 12
Number of subjects: 338
Study 24361229 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with assessment of response at week 12 for ERMS
Number of subjects: 338
Study 24361229 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with assessment of response at week 12 for ARMS
Number of subjects: 338
Study 22697080 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS) with epinephrine
Number of subjects: 0
Study 22697080 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) with epinephrine
Number of subjects: 0
Study 20831697 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath PUVA
Number of subjects: 34
Study 20831697 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 34
Study 17350688 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser (IntraLase FS)
Number of subjects: 21
Study 17350688 — intervention group
Group type: COMPARATOR
Intervention: Mechanical microkeratome (Hansatome)
Number of subjects: 21
Study 16376766 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic response during dipyridamole echocardiography test (DET)
Number of subjects: 80
Study 16376766 — intervention group
Group type: COMPARATOR
Intervention: Sustained improvement in regional contractility
Number of subjects: 80
Study 16376766 — intervention group
Group type: COMPARATOR
Intervention: No change in contractility
Number of subjects: 80
Study 16376766 — intervention group
Group type: COMPARATOR
Intervention: Worsening response
Number of subjects: 80
Study 16579082 — intervention group
Group type: EXPERIMENTAL
Intervention: Jian Nao Ning (JNN)
Number of subjects: 40
Study 16579082 — intervention group
Group type: COMPARATOR
Intervention: duxil
Number of subjects: 40
Study 9854467 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyrate enemas
Number of subjects: 10
Study 9854467 — intervention group
Group type: COMPARATOR
Intervention: Saline enemas
Number of subjects: 10
Study 7611002 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (BOTOX) 0.5 U/site
Number of subjects: 0
Study 7611002 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (BOTOX) 1.25 U/site
Number of subjects: 0
Study 7611002 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A (BOTOX) 2.5 U/site
Number of subjects: 0
Study 2230552 — intervention group
Group type: EXPERIMENTAL
Intervention: Goode T-tube
Number of subjects: 15
Study 2230552 — intervention group
Group type: COMPARATOR
Intervention: Armstrong tube
Number of subjects: 15
Study 646600 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape immediate feedback during rehabilitation sessions (four sessions at weekly intervals)
Number of subjects: 12
Study 646600 — intervention group
Group type: COMPARATOR
Intervention: Control group (videotaped but did not view tapes or discuss performances)
Number of subjects: 12
Study 31852491 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoKinetics
Number of subjects: 336
Study 31852491 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing (Control)
Number of subjects: 336
Study 27883997 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4BN (Internet-based manualized CBT group therapy)
Number of subjects: 179
Study 27883997 — intervention group
Group type: COMPARATOR
Intervention: CBTF2F (traditional face-to-face group therapy)
Number of subjects: 179
Study 25827507 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lithium added to optimized treatment (OPT)
Number of subjects: 283
Study 25827507 — intervention group
Group type: COMPARATOR
Intervention: Optimized treatment (OPT) alone
Number of subjects: 283
Study 23387340 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 73
Study 23387340 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration
Number of subjects: 73
Study 23387340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 21029208 — intervention group
Group type: EXPERIMENTAL
Intervention: synchronous balneophototherapy (sBPT)
Number of subjects: 180
Study 21029208 — intervention group
Group type: COMPARATOR
Intervention: narrow-band UVB monotherapy (PT)
Number of subjects: 180
Study 19899672 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment using empatho-techniques
Number of subjects: 0
Study 19899672 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 0
Study 16964862 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRD formula‐based dosimetric method
Number of subjects: 89
Study 16964862 — intervention group
Group type: COMPARATOR
Intervention: Fixed-lambda(eff) method
Number of subjects: 89
Study 12934418 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 128
Study 12934418 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 128
Study 12934418 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 50
Number of subjects: 128
Study 12934418 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 128
Study 11014095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 9089983 — intervention group
Group type: EXPERIMENTAL
Intervention: Single donor platelet‐pheresis products (SD‐PC)
Number of subjects: 51
Study 9089983 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets made from pooled buffy coats (BC‐PC)
Number of subjects: 51
Study 9089983 — intervention group
Group type: COMPARATOR
Intervention: Pooled units of platelets made by the platelet‐rich plasma method (PRP‐PC)
Number of subjects: 51
Study 8196254 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (35 mg/day)
Number of subjects: 22
Study 8196254 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (0.31 mg/day)
Number of subjects: 22
Study 3529832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole
Number of subjects: 0
Study 3529832 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 30904707 — intervention group
Group type: EXPERIMENTAL
Intervention: Psych group (patients with pre-existing psychiatric diagnoses)
Number of subjects: 1275
Study 30904707 — intervention group
Group type: COMPARATOR
Intervention: Non-psych group (patients without pre-existing psychiatric diagnoses)
Number of subjects: 1275
Study 28095971 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed severe obstructive sleep apnea (apnea-hypopnea index ≥ 30 events/h)
Number of subjects: 788
Study 28095971 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with OSA and excessive daytime sleepiness (Epworth Sleepiness Scale score of 10 or higher)
Number of subjects: 788
Study 26204531 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell intracoronary transplantation (mean dose of 8.19 ± 4.43 x 10(6) CD34+ cells)
Number of subjects: 23
Study 26204531 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study 22834764 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from social network and nurses
Number of subjects: 164
Study 22834764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 164
Study 22049165 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded intakes of protein (0.1-2.56 g · kg(‐1) · d(‐1))
Number of subjects: 7
Study 22049165 — intervention group
Group type: COMPARATOR
Intervention: Current DRI recommendations for protein (0.76 g · kg(‐1) · d(‐1))
Number of subjects: 7
Study 19892301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 microg/kg/day for 2 days, repeated within 2 weeks, every 6 months if persisting immunosuppression
Number of subjects: 0
Study 16537862 — intervention group
Group type: EXPERIMENTAL
Intervention: aCPAP (autoadjusted continuous positive airway pressure)
Number of subjects: 30
Study 16537862 — intervention group
Group type: COMPARATOR
Intervention: cCPAP (constant continuous positive airway pressure)
Number of subjects: 30
Study 16537862 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference
Number of subjects: 30
Study 15253822 — intervention group
Group type: EXPERIMENTAL
Intervention: Acucise endopyelotomy
Number of subjects: 22
Study 15253822 — intervention group
Group type: COMPARATOR
Intervention: Hynes‐Anderson pyeloplasty
Number of subjects: 22
Study 11315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital radiography
Number of subjects: 0
Study 11315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-developing film
Number of subjects: 0
Study 11315476 — intervention group
Group type: COMPARATOR
Intervention: Manually processed film
Number of subjects: 0
Study 11315476 — intervention group
Group type: COMPARATOR
Intervention: Film developed in an automatic processor
Number of subjects: 0
Study 11315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital images on a liquid crystal diode
Number of subjects: 0
Study 11315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital images on a cathode ray tube screen
Number of subjects: 0
Study 9160991 — intervention group
Group type: EXPERIMENTAL
Intervention: Exculpatory clauses present in the contract
Number of subjects: 101
Study 9160991 — intervention group
Group type: COMPARATOR
Intervention: Exculpatory clauses not present in the contract
Number of subjects: 101
Study 7957448 — intervention group
Group type: EXPERIMENTAL
Intervention: MSP (20 mg base of mefloquine/kg body weight)
Number of subjects: 23
Study 7957448 — intervention group
Group type: COMPARATOR
Intervention: MSP plus primaquine (0.75 mg/kg)
Number of subjects: 23